Pregnant women who do not get enough sleep may be at higher risk of having children with neurodevelopmental delays, a new ...

Shares of Merck (NYSE:MRK) traded marginally higher on Friday after falling from a high of $119.38 from the past seven ...

Barron’s 2024 Healthcare Roundtable panelists make the case for 21 healthcare companies of all stripes, including Humana, ...

Beyond acquisitions, we continue to expect steady future dividends, supported by a payout ratio of close to 50% relative to adjusted earnings per share. Patents, economies of scale, and a powerful ...

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

The vaccine race: it was Brexit and Bingham what won it. There were good reasons for any member of the Tory Government to ...

By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Janux ...

The Prevnar 20 approval comes a few weeks ahead of an FDA decision on Merck's V114, which was granted a priority review by the regulator in January for the prevention of IPD in adults.

Qure.ai Technologies Pvt. Ltd, a health-tech startup that uses artificial intelligence for medical imaging diagnostics, has ...